Bone metastases: State of the art in minimally invasive interventional oncology

Anderanik Tomasian, Jack W. Jennings

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Bone is the third most common site involved by cancer metastases, and skeleton-related events such as intractable pain due to direct osseous tumor involvement, pathologic fracture, and neurologic deficits as a consequence of nerve or spinal cord compression often affect patients’ functional independence and quality of life unfavorably. The annual medical-economic burden related to bone metastases is a substantial component of the total direct medical cost estimated by the National Institutes of Health. There have been substantial recent advances in percutaneous image-guided minimally invasive musculoskeletal oncologic interventions for the management of patients with osseous metastatic disease. These advances include thermal ablation, cementation with or without osseous reinforcement with implants, osteosynthesis, thermal and chemical neurolyses, and palliative injections, which are progres-sively incorporated into the management paradigm for such pa-tients. These interventions are performed in conjunction with or are supplemented by adjuvant radiation therapy, systemic therapy, surgery, or analgesic agents to achieve durable pain palliation, local tumor control, or cure, and they provide a robust armamentarium for interventional radiologists to achieve safe and effective treatment in a multidisciplinary setting. In addition, these procedures are shifting the patient management paradigm in modern-era prac-tice. The authors detail the state of the art in minimally invasive percutaneous image-guided musculoskeletal oncologic interventions and the role of radiologists in managing patients with skeletal metastases.

Original languageEnglish
Pages (from-to)1475-1492
Number of pages18
Issue number5
StatePublished - Sep 1 2021


Dive into the research topics of 'Bone metastases: State of the art in minimally invasive interventional oncology'. Together they form a unique fingerprint.

Cite this